TYRA Initiates Phase 2a/b Clinical Trial of Dabogratinib for Low-Grade Upper Tract Urothelial Carcinoma, Dosing First Patient
SURF303 Trial Commences with First Patient Dosing and Pivotal Design for Regulatory Approval
Tyra Biosciences (TYRA) has initiated the global Phase 2a/b SURF303 (NCT07265947) trial, evaluating dabogratinib (developmental name: TYRA-300) in patients with low-grade upper tract urothelial carcinoma (LG-UTUC). This trial is designed with a pivotal intent, potentially leading directly to a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The study aims to enroll approximately 230 patients to assess personalized treatment efficacy based on tumor size and genomic variations, demonstrating the utility of precision medicine.
Differentiated Mechanism of Action for an Oral, Selective FGFR3 Inhibitor
Dabogratinib is an innovative, oral targeted therapy that selectively inhibits fibroblast growth factor receptor 3 (FGFR3), a key driver of tumor growth. First-generation pan-FGFR inhibitors have limitations due to non-selective binding, leading to significant side effects such as hyperphosphatemia, nail changes, and stomatitis, hindering long-term administration. In contrast, dabogratinib is designed to minimize off-target toxicity, potentially improving patient compliance and tolerability, and enhancing treatment duration.
Addressing Unmet Needs by Replacing Invasive Standard Treatment
Approximately 85% of LG-UTUC patients harbor FGFR3 mutations, making them a well-defined target population for dabogratinib. Currently, the only FDA-approved treatment, Jelmyto from UroGen Pharma, utilizes a reverse thermal hydrogel technology for chemotherapy, but it involves highly invasive administration through a ureteral catheter or nephrostomy tube. The availability of dabogratinib, an easily administered oral therapy, could significantly improve the quality of life for patients by eliminating the need for complex urological procedures.
Standalone Development Strategy and the Value of the Proprietary SNÅP Platform
Tyra Biosciences is independently developing dabogratinib using its proprietary SNÅP molecular design platform, without relying on partnerships or licensing agreements. This platform has already demonstrated its value by securing Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for achondroplasia, a rare pediatric disease. By independently leading the pivotal clinical trial in upper tract urothelial carcinoma, Tyra aims to maximize its financial rights and potential profits during the commercialization phase.
Upcoming Milestones and Commercial Market Outlook
The initial efficacy and safety data from the SURF303 trial are expected in 2027, which will be a critical inflection point for Tyra's valuation. With Jelmyto, a competing drug, generating $94 million in net sales in 2025 and dominating a niche market, dabogratinib, with its enhanced convenience, has the potential to rapidly capture market share. It is expected to generate strong demand, particularly among older patients who wish to avoid radical nephroureterectomy, the standard treatment.
Dabogratinib is entering a pivotal Phase 2a/b trial (SURF303) with the potential for regulatory approval, offering the first oral targeted therapy option for patients with low-grade upper tract urothelial carcinoma (LG-UTUC), a patient population where approximately 85% harbor FGFR3 mutations. Compared to Jelmyto, the only FDA-approved competitor with $94 million in net sales in 2025, which requires invasive catheter-based administration, dabogratinib's oral administration offers a unique and significant convenience, potentially securing strong market dominance upon commercialization. Clinically, it addresses the limitations of existing pan-FGFR inhibitors by selectively targeting the receptor, potentially demonstrating superior long-term tolerability. The company's independent development strategy allows it to retain 100% of the intellectual property and financial rights, which is expected to significantly contribute to the long-term value of Tyra Biosciences, potentially enabling a standalone commercialization or a lucrative mega-deal with a larger pharmaceutical company.
Source: ClinicalTrials.gov (api_ct)